Premium
New 2‐Oxoimidazolidine Derivatives: Design, Synthesis and Evaluation of Anti‐BK Virus Activities in Vitro
Author(s) -
Kornii Yurii,
Chumachenko Svitlana,
Shablykin Oleg,
Prichard Mark N.,
James Scott H.,
Hartline Caroll,
Zhirnov Victor,
Brovarets Volodymyr
Publication year - 2019
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.201900391
Subject(s) - cidofovir , chemistry , in vitro , cytotoxicity , selectivity , bk virus , bioassay , stereochemistry , combinatorial chemistry , pharmacology , virus , virology , organic chemistry , biochemistry , biology , genetics , catalysis , kidney transplantation , kidney , endocrinology
A series of novel 2‐oxoimidazolidine derivatives were synthesized and their antiviral activities against BK human polyomavirus type 1 (BKPyV) were evaluated in vitro . Bioassays showed that the synthesized compounds 1‐{[(4 E )‐5‐(dichloromethylidene)‐2‐oxoimidazolidin‐4‐ylidene]sulfamoyl}piperidine‐4‐carboxylic acid ( 5 ) and N ‐Cyclobutyl‐ N ′‐[(4 E )‐5‐(dichloromethylidene)‐2‐oxoimidazolidin‐4‐ylidene]sulfuric diamide ( 4 ) exhibited moderate activities against BKPyV (EC 50 =5.4 and 5.5 μ m , respectively) that are comparable to the standard drug Cidofovir. Compound 5 exhibited the same cytotoxicity in HFF cells and selectivity index (SI 50 ) as Cidofovir. The selectivity index of compound 4 is three times less than that of Cidofovir due to the higher toxicity of this compound. Hence, these compounds may be taken as lead compound for further development of novel ant‐BKPyV agents.